According to the IMARC Group, preeclampsia market reached a value of US$ 712.3 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 856.5 Million by 2034, exhibiting a growth rate (CAGR) of 1.69% during 2024-2034. This can be attributed to the emerging popularity of angiogenic biomarkers, which accelerate diagnosis and minimize adverse maternal outcomes to help enable risk stratification, along with appropriate resource redistribution.

Preeclampsia represents a pregnancy-related complication that mainly affects after the 20th week of pregnancy and is recognized by high blood pressure and damage to organs, such as the liver and kidneys. The preeclampsia market is primarily driven by the rising prevalence of maternal hypertension, increasing awareness about prenatal care, and advancements in diagnostic screening techniques. Besides this, the growing adoption of predictive biomarkers, such as placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1), has significantly improved early detection and risk assessment, thereby fueling the preeclampsia market growth. The increasing availability of non-invasive diagnostic tools, including blood tests and wearable monitoring devices, is further enhancing early intervention strategies.

Request for a sample of this report: https://www.imarcgroup.com/preeclampsia-market/requestsample

Countries Covered:

United States

Germany

France

United Kingdom

Italy

Spain

Japan

Analysis Covered Across Each Country:

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the Preeclampsia Market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the Preeclampsia Market

Reimbursement scenario in the market

In-market and pipeline drugs

This report also provides a detailed analysis of the current Preeclampsia Market drugs and late-stage pipeline drugs.

In-Market Drugs:

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs:

Drug overview

Mechanism of action

Regulatory status

Clinical trial results

Drug uptake and market performance

Ask the Analyst for Customization and Explore the Full Report with TOC: https://www.imarcgroup.com/preeclampsia-market

Competitive Landscape with key players:

The competitive landscape of the Preeclampsia Market has been studied in the report with the detailed profiles of the key players operating in the market.

1. Kyowa Kirin

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145